^
    Back
    Association details:
    Biomarker:HER-2 L755P
    Cancer:Non Small Cell Lung Cancer
    Drug:AEE788 (EGFR inhibitor, HER2 inhibitor, Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

    Excerpt:
    Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and lung cancer....While ERBB2-L755S and ERBB2-L755P mutants remained sensitive to AEE788 at very high concentrations (IC90 below 2 µM), the gatekeeper ERBB2-T798M mutation is totally resistant (IC50>2 µM) to AEE788 treatment...
    DOI:
    10.1371/journal.pone.0026760